News Category
Tonix Pharmaceuticals will present its investigational TNX-801 vaccine platform for mpox at the World Vaccine Congress Europe, highlighting its potent...
OrthodontiCell has secured sufficient capital to complete the remaining testing needed to support its application for a planned Phase II pivotal clini...
hyperCORE International has elected Jeffrey Smyth as President, Seneca Harrison as Vice President, and Claxton Copeland as Secretary, with Dustin Owen...
Quantum BioPharma has received FDA approval to begin Phase 2 clinical testing of Lucid-MS, a potential first-in-class multiple sclerosis therapy that ...
The American Heart Association has selected five health technology companies as finalists for its 2026 Health Tech Competition, aiming to accelerate i...
NanoViricides reports progress in its Phase IIA trial of NV-387 Oral Gummies for Ebola Bundibugyo virus, potentially leading to a Phase IIB study and ...
Nutriband Inc. has raised approximately $1.75 million through warrant exercises, funds it will use to support clinical development and a New Drug Appl...
Leksum LLC has signed an agreement with the Medical University of Vienna to prepare for first-in-human clinical trials of LK-ICU, a therapy that may p...
The American Heart Association has launched a comprehensive education portfolio to help clinicians apply the new cardiovascular-kidney-metabolic (CKM)...
Newron Pharmaceuticals has received FDA feedback on a clinical hold at U.S. sites for its Phase 3 ENIGMA-TRS 2 trial of evenamide, but remains confide...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement the Phase 2 trial of L...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to launch a Phase 2 trial of Lucid-MS, a new m...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to initiate a Phase 2 trial of Luci...
XORTX Therapeutics is advancing its gout treatment XORLO toward a New Drug Application with the FDA, aiming to address the limitations of current ther...
Quantum BioPharma has entered a Study Start-Up Agreement with Thermo Fisher Scientific to initiate Phase 2 trial activities for Lucid-MS, a potential ...
NanoViricides will present at the NIBA 153rd Investment Conference on Oct. 7, 2026, highlighting its broad-spectrum antiviral NV-387, which is in Phas...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific to implement its Phase 2 trial of Lucid-MS for multiple sclerosi...
Okogen's Treyegen (OKG-0303) has received CDSCO authorization to begin a Phase 1/2 trial in India, potentially offering the first single therapy for b...
NanoViricides is progressing its Phase II clinical trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus in the Democratic Republic of Congo, with en...
Nutriband Inc. celebrates five years on Nasdaq with key milestones in its abuse-deterrent fentanyl patch and outlines upcoming regulatory steps.
Gianluca Cerri, MD, is promoting a personal policy that emergency physicians should discuss medication-assisted treatment with opioid use disorder pat...
Stonegate Capital Partners' updated coverage highlights Incannex Healthcare's progress with IHL-42X, which has moved into active clinical execution wi...
A new novel by AAG Zacheriel explores the consequences of compromised clinical trial data, raising timely questions about trust in medical research an...
Quantum BioPharma is advancing its multiple sclerosis drug candidate Lucid-MS into Phase 2 trials while also holding a stake and royalty stream in the...
Quantum BioPharma is advancing its Lucid-MS drug candidate to a Phase 2 trial in multiple sclerosis patients and is highlighting the commercial potent...
A new NFID survey shows 77% of U.S. adults support vaccines, but only 48% got a respiratory vaccine in the past year, highlighting gaps in awareness a...
NanoViricides reported fiscal 2026 results, highlighting regulatory approval for Phase II trials of NV-387 in the Democratic Republic of Congo and FDA...
NanoViricides has launched patient enrollment and dosing in a Phase II trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus and other Ebola viruses ...
Quantum BioPharma's lead MS drug candidate, Lucid-MS, has received FDA approval of its Investigational New Drug application, enabling the company to l...
Nutriband Inc. appoints former Navy SEAL Robert J. O'Neill to its advisory board, bringing strategic expertise as the company advances its abuse-deter...
Creative Biolabs has introduced a three-part antibody engineering framework to help researchers overcome immunogenicity, efficacy, and developability ...
FamiCord AG's CDMO division, Bramble Bio, will manufacture VERIGRAFT's personalized tissue-engineered vein P-TEV for a pivotal Phase II/III trial, in ...
Quantum BioPharma has received FDA approval to advance its multiple sclerosis drug candidate Lucid-MS into Phase 2 clinical testing, potentially offer...
Annovis Bio's collaboration with Weave Bio to prepare its NDA for buntanetap using AI could streamline regulatory filing and impact the treatment land...
Dr. Katherine R. Tuttle will receive the American Heart Association's 2026 Clinical Research Prize for her pioneering work in chronic kidney disease a...
Boston BioLife marks 11 years of translational medicine leadership by co-presenting the Translational Longevity Summit, aiming to bridge the gap betwe...
Tonix Pharmaceuticals' second major managed Medicare agreement for TONMYA expands coverage to 32 million Medicare lives and 166 million total covered ...
In vitro ADME studies are becoming essential for efficient drug development, helping to identify promising candidates early and avoid costly late-stag...
A new study reveals that the risk of sepsis, meningitis, or pneumonia from air pollution depends on an individual's bacterial strains, highlighting th...
Peptide Wholesale Supply has extended its HPLC peptide testing protocols to bulk orders of BPC-157, Semaglutide, and Tirzepatide, aiming to improve ba...
Medical experts are urging small cell lung cancer patients to ask about clinical trials at their first appointment, as emerging treatments offer new h...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the GEO-MVA Phase 3 trial could lead to an additional qualified source of m...
Tevard Biosciences and collaborators published preclinical research demonstrating that engineered suppressor tRNAs can restore full-length dystrophin ...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities to help researchers overcome stability, targetin...
BioCorRx Inc. appoints Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Advisory Bo...
Regentis Biomaterials reported a reduced net loss for the first half of 2026 and progress in its pivotal U.S. trial for GelrinC, a potential off-the-s...
Quantum BioPharma has received FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug that aims to protect and ...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, with European approval and an FD...
